Project Name: Royal Free Neuroendocrine Tumours (NETs) Service Expansion
Project Summary:
This Collaborative Working Agreement (CWA) aims to recruit one FTE Neuro Endocrine Tumour (NETs) Fellow to support the collaboratove working (CW) partner with the co-ordination of the review, management, and treatment of patients within the NETs Service.
The recruitment of the NETs Fellow is part of a wider programme of works to expand the NETs Service within the Trust.
The expected outcomes of this Collaborative Working Project (CWP) are as follows.
- Increase in the number of NETS patients seen in the NETs Service
- Improvement in the time from decision to treat to first initiation
- Increased capacity to allow more treatments to be administered.
- Interval times between treatment more effectively monitored and adhered to.
The improved outcomes from the service expansion will enable a business case to be developed by the trust for permanent provision to ensure long term sustainability of the project.
Planned Milestones:
| Milestone | Description |
|---|---|
| 1 | CW Partner and Novartis: Kick-off meeting. |
| 2 | CW Partner: Confirmation of live advertisement for the recruitment of NETs Fellow. |
| 3 | CW Partner: Confirmation of interview dates for the recruitment of NETs Fellow. |
| 4 | CW Partner: Confirmation of recruitment of NETs Fellow. CW Partner: Confirmation of clinical and operational pathway, policy and protocol creation, and readiness to begin the clinical activity. |
| 5 | CW Partner: Collection of baseline data. |
| 6-9 | CW Partner: Collection & Submission of clinical activity data every three months. CW Partner and Novartis: Project review meeting to discuss project progress. |
| 10 | CW Partner: Collection & submission of Fifteen months clinical activity data. Initiation of development of Business Case. CW Partner and Novartis: Project Review meeting to discuss project progress. |
| 11-13 | CW Partner: Collection & submission of clinical activity data every three months. CW Partner and Novartis: Project Review meeting to discuss project progress. |
| 14 | CW Partner: Completion and submission of business case by the CW Partner team to relevant body within the NHS Board. |
| 15 | CW Partner: Submit final CWP report to Novartis within 2 months completion of the clinical work. |
Expected Benefits:
ANTICIPATED BENEFITS FOR PATIENTS
- Reduction in time to treatment from a decision to treat.
- Improved disease awareness, treatment information and access to advanced NETs therapies
- Increased availability of hospital appointments required for therapy.
- Clinical support for patients related to therapy once initiated.
ANTICIPATED BENEFITS FOR THE ORGANISATION(S)
- Clinical and administrative support for a busy clinical service
- Ability to meet the needs of a wider cohort of patients who may be eligible for Advanced NETs Therapy, ensuring greater equity of access to innovative treatments.
- Improving the interface with referral centres
- Improved triaging across the region to meet demand.
- Improved capacity in NETS clinics
- Branding and reputational impact for the Trust
ANTICIPATED BENEFITS FOR NOVARTIS
- Increased access to Advanced NET therapies (which may include Novartis therapies)
- Reduction in geographical variation in therapy use
- Raised awareness of NETs treatments in the region
- Increased reputation for collaboration.
Start Date & Duration: September 2024 for 34 months
UK | September 2024 | FA-11262860